Counting the cost of treating benign prostatic hyperplasia

BJU International

Volumn 93, Issue 3, 2004, Pages 250-252

  Foley, C L ^a   Taylor, C ^b   Kirby, R S ^a  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; FINASTERIDE;

CALCULATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HUMAN; NOTE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SIDE EFFECT; TREATMENT OUTCOME;

COSTS AND COST ANALYSIS; HUMANS; MALE; PROSTATIC HYPERPLASIA;

EID: 1342267599     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04595.x     Document Type: Note

References (4)

1. McConnell JD, for the MTOPS Steering Committee. The long term effects of medical therapy on the progression of BPH; results from the MTOPS trial. J Urol 2002; 167(Suppl. 4): 265, Abs
2. McConnell J, Barry M, Bruskewitz R et al. Benign Prostatic Hyperplasia. Diagnosis and treatment. Clinical Practice Guidelines, no. 8. AHCPR Publication No. 940582. Rockville, MD. Agency for Health Care Policy and Research, Public Health Service: US Department of Health and Human Services, 1994
3. Canadian Coordinating office for Health Technology Assessment. Cost-effectiveness and cost-utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia. Ottawa: CCOHTA, 1995
4. Verhamme KM, Dieleman JP, Bleumink GS et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care - the TRIUMPH project. Eur Urol 2002; 42: 323-8